Research Desk Line-up: Analogic Post Earnings Coverage
LONDON, UK / ACCESSWIRE / June 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for the leading genetic information Company, Invitae Corp. (NYSE: NVTA). The Company announced on June 12, 2017, that it has acquired Ommdom, Inc., the developer of CancerGene Connect, and other healthcare software. CancerGene Connect is one of the most efficient, end-to-end platforms available for collecting, assessing and managing genetic family histories. It is the next-gen genetic assessment platform which offers the user intuitive access at his fingertips, with over 2,000 available data points per patient. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Medical Laboratories & Research industry. Pro-TD has currently selected Analogic Corporation (NASDAQ: ALOG) for due-diligence and potential coverage as the Company announced on June 06, 2017, its financial results for Q3 which ended on April 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Analogic when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NVTA; also brushing on ALOG. Go directly to your stock of interest and access today's free coverage at:
Cancergene was developed by clinicians to streamline the processes of collection, analysis, and management of patient family history information. The platform leverages a cloud-based, mobile friendly patient interface to collect family history information prior to an on-site clinician appointment. The data collection, once completed, enables the use of powerful analysis tools that use the latest research on hereditary risk, to analyze a patient's predisposition to disease and deliver actionable analysis to inform therapeutic decisions, including genetic testing or treatment methods. The platform additionally offers the clinicians to look beyond the individual and observe trends across all patients, as a whole.
About the Announcement
Cancergene Connect encourages family history collection by the patients before their genetics appointment, as it assembles more detailed and concise information. The analysis tool designed to the data available offers depth and flexibility to cater the genetic history according to each individual patient. CancerGene Connect was first created in the late 1990s at UT Southwestern Medical Center, where the center developed and the initial version of the tool which enabled the clinicians to run complex risk assessment algorithms that initially required time-intensive research calculations for each patient. In 2013, UT Southwestern Medical Center won the Innovator Award from the Association of Community Cancer Centers, for its work on CancerGene Connect.
Ommdom currently holds the exclusive license from UT Southwestern Medical Center to further develop and commercialize CancerGene Connect. Under terms of the agreement, Invitae acquired all the Ommdom's outstanding capital for about $6 million in Invitae's common stock. Invitae currently holds a portfolio of more than 1,500 genes for a variety of genetic disorders and other rare disease areas and the clinical analysis of a 20,000-gene medical exome.
Company Growth Prospects
On April 20, 2017, Invitae announced the addition of 80 new panels in addition to an additional 24 panels for the diagnosis of inherited immunologic and metabolic disorders. The new and updated tests further expanded the Company's robust portfolio of affordable diagnostic genetic tests available for use by clinicians.
Invitae also introduced exome testing on March 30, 2017, where it announced a major expansion of its genetic testing services with the introduction of exome sequencing and interpretation services, hence expanding the Company's existing portfolio to more than 20,000 genes. Invitae performs high-quality exome testing, using next-gen sequencing (NGS) technology to analyze the coding regions, also named as exons for up to 20,000 genes. Invitae's Boost Exome assesses these changes with customized bioinformatics and rigorous implementation in an attempt to identify the origin of a genetic disease.
Last Close Stock Review
At the closing bell, on Tuesday, June 13, 2017, Invitae's stock climbed 1.42%, ending the trading session at $9.31. A total volume of 164.27 thousand shares were traded at the end of the day. In the last six months and previous twelve months, shares of the Company have soared 28.59% and 18.60%, respectively. Moreover, the stock rallied 17.25% since the start of the year. The stock currently has a market cap of $385.71 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily